Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Impact of Iclusig: Access Program May Have Important Implications For Personalized Medicine

This article was originally published in RPM Report

Executive Summary

FDA’s decision to seek the withdrawal of Ariad’s Iclusig prompted concerns about greater caution by the agency in the “Breakthrough” era. A more important implication, however, may be in whether the continued access program succeeds in meeting demand for the product. That could become a model for future development of ever-more personalized cancer treatment regimens.


Related Content

The Next Phase In Oncology: FDA’s Pazdur On “Breakthrough” Drug Development
Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts